Has acquired Bio-Pharm, a generic and overthe-counter drugmaker based in Levittown, Pennsylvania, for an undisclosed sum. “This acquisition is an important step for increasing Torrent’s presence in the United States, is consistent with our strategy of dosage form diversification, and provides us with new capabilities including manufacturing and R&D presence in the USA,” the Ahmedabad-based company said on Thursday.

Torrent Pharmaceuticals Ltd. Company Profile: Read about Torrent Pharma. Of 3 new divisions – Prima, Vista, Psycan; Patents first new chemical via Torrent.

Bio-Pharm, Inc. (BPI), which has a 75,000 sqft manufacturing facility, boasts of 10 abbreviated new drug applications (ANDAs) already approved by the (FDA).

It has another 10 ANDAs — or applications for approval of a generic drug product — under review at while its partners have an additional 17 products under development. Torrent Pharma said it plans further investments to expand the BPI facilities, including its research and development (R&D) capabilities, and increase the number of product filings from BPI.

This is the third acquisition for Torrent Pharma in the last three years. Last year it had acquired business of to strengthen its presence in the domestic market.

Cara menggunakan software maktabah syamilah. Lebih mudah dan cepat walau tak menghapus pentingnya kitab asli, dengan maktabah syamilah insyaAllah banyak hal menjadi lebih mudah. Yang sekarang versi 3.48, kita tunggu update selanjutnya. Selalu tersedia update berkala. Ada banyak fitur menarik mulai dari kecepatan pencarian, pencatatan dan berbagai kemudahan lainnya yang tidak di dapat pada kitab fisik lainnya.

• Baddi Plant received OHAS Audit certification; facility approved by the regulatory authority of Uganda • An advanced facility for Stability Studies set up at Indrad Plant • Entered into the therapeutic area of Gynaecology • Commenced commercial operations of Laboratories Torrent S.A. De C.V., Mexico • Started construction of Dahej manufacturing facility • Commissioned a subsidiary in United Kingdom and Romania • Torrent Research Center develops Long Acting Injectables technology • Foray into oncology segment •. • New manufacturing unit at Baddi, Himachal Pradesh, set up to cater to domestic formulations market. • Torrent Pharma signed an agreement with Novo Nordisk India to establish a new, dedicated formulation and packaging facility for Insulin, exclusively for Novo Nordisk. • Acquired Heumann Pharma GmbH & Co Generica KG, a Pfizer group company, in Germany. • Two new marketing divisions- AXON and NEURON set up to cater to neuropsychiatry segment.

• Entered into a research collaboration with AstraZeneca for developing novel anti-hypertensive drug. • Torrent Pharma's QC department at Chhatral manufacturing plant accredited with ISO/IEC- 17025 by NABL •. • Discovered and patented AGE (Advanced Glycosylation End-products) molecule. • Torrent Pharma's Indrad Plant receives ISO and OHSAS • Torrent's R&D Centre received ISO/IEC for its facilities by National Accreditation Board for Testing and Calibration Laboratories (NABL).

• Addition of a new marketing division, MIND • Dual Retard Inlay Technology, Compact Tablet Technology, Gastro Retentive System and Multiparticulate / Matrix Based SR / Modified Release Formulations developed indigenously by Torrent Research Center (2002) • Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award 2003 for both Formulations and API manufacturing facilities • Brazilian Sanitary Surveillance Agency accredited Torrent's R&D Centre with ANVISA, authorizing it to conduct Bioequivalance Studies.